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ABSTRACT  Recent advances in immunology and cancer research 
show that fatty acids, their metabolism and their sensing have a cru-
cial role in the biology of many different cell types. Indeed, they are 
able to affect cellular behaviour with great implications for patho-
physiology. Both the catabolic and anabolic pathways of fatty acids 
present us with a number of enzymes, receptors and ago-
nists/antagonists that are potential therapeutic targets, some of 
which have already been successfully pursued. Fatty acids can affect 
the differentiation of immune cells, particularly T cells, as well as 
their activation and function, with important consequences for the 
balance between anti- and pro-inflammatory signals in immune dis-
eases, such as rheumatoid arthritis, psoriasis, diabetes, obesity and 
cardiovascular conditions. In the context of cancer biology, fatty ac-
ids mainly provide substrates for energy production, which is of cru-
cial importance to meet the energy demands of these highly prolif-
erating cells. Fatty acids can also be involved in a broader transcrip-
tional programme as they trigger signals necessary for tumorigenesis 
and can confer to cancer cells the ability to migrate and generate 
distant metastasis. For these reasons, the study of fatty acids repre-
sents a new research direction that can generate detailed insight and 
provide novel tools for the understanding of immune and cancer cell 
biology, and, more importantly, support the development of novel, 
efficient and fine-tuned clinical interventions. Here, we review the 
recent literature focusing on the involvement of fatty acids in the 
biology of immune cells, with emphasis on T cells, and cancer cells, 
from sensing and binding, to metabolism and downstream effects in 
cell signalling.  
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Abbreviatons: 
ACC – acetyl-CoA carboxylase, ACLY – ATP citrate 
lyase, CPT – carnitine palmitoyl transferases, CRPC – 
castration-resistant prostate cancer, DHA – 
docosahexaenoic acid, EAE – experimental 
autoimmune encephalomyelitis, EMT – epithelial to 
mesenchymal transition, EPA – eicosapentaenoic 
acid, FABP – Fatty acid binding protein, FADS – fatty 
acyl-CoA desaturase, FAS – fatty acid synthase, GA – 
gastric adenocarcinoma, HCC – hepatocellular 
carcinoma, HDAC – histone deacetylase, HFD – high 
fat diet, ILC – innate lymphoid cell, LAL – lysosomal 
acid lipase, LMW-E – low molecular weight isoform 
of cyclin E, LPS – lipopolysaccharide, mCRPC – 
metastatic CRCP, NK – natural killer, PI(4,5)P2 – 
phosphatidylinositol (4,5) bisphosphate, PLD – 
phospholipase D, PPAR – peroxisome proliferator-
activated receptor, PUFA – polyunsaturated fatty 
acid, SCD – stearoyl-CoA desaturase, SREBP – sterol 
regulatory element binding protein, Tconv – 
conventional T cell, TCR – T cell receptor, Teff – T 
effector cell, Th – T helper cell, Tm – T memory cell, 
TNBC – triple-negative breast cancer, Treg – 
regulatory T cell, wt – wild type. 
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INTRODUCTION 
Lipids are important biomolecules involved in a plethora of 
biological processes, spanning from the production and 
storage of energy [1] and assembly and function of the 
cellular membranes [2] to activation of genes [3] and mod-
ulation of signalling pathways [4]. This diverse group of 
compounds comprises fatty acids, glycerolipids, glycer-
ophospholipids, sphingolipids, sterol lipids, prenol lipids, 
saccharolipids and polyketides [5-7]; typically, the cellular 
lipidome comprises more than 2,000 species. This structur-
al diversity endows lipids with varied properties that ena-
ble and support a plethora of structural and functional 
roles.  
As lipids are not encoded, their levels are regulated 
both by nutritional intake and biosynthetic pathways found 
in almost all cell types. Fatty acids are simple lipids biosyn-
thesised by the complex enzyme fatty acid synthase (FAS) 
through the sequential elongation of acetyl-CoA [8]. The 
resulting 16-carbon (C) acyl chain palmitic acid can be fur-
ther elongated and desaturated. However, humans and 
other animals require nutritional intake of two essential 
fatty acids -linoleic acid and alpha-linolenic acid - precur-
sors to long and very long polyunsaturated fatty acids 
(PUFA). As well as contributing to the structural diversity of 
membrane glycerophospholipids and sphingolipids, PUFA 
are metabolised to potent autacoids, hormone-like media-
tors known for their involvement in inflammation and im-
munity [9-11], while the catabolism of fatty acids via β-
oxidation provides the cells with an efficient way for ener-
gy production. Membrane glycerophospholipids and sphin-
golipids, as well as acylglycerols (e.g. triacylglycerols) act as 
cellular pools of esterified fatty acids that can be liberated 
and further metabolised to meet the energy and other 
biosynthetic needs of different cell types. 
In this review, we are discussing the involvement of fat-
ty acids in immunity, particularly in T cells, and cancer, with 
focus on their roles as energy substrates, regulators of cell 
survival, proliferation and effector function. Increasing 
evidence supports the notion that fatty acids can influence 
the biological behaviour of immune and other cell types 
when involved in pathophysiological conditions, such as 
metabolic disorders, autoimmune diseases and cancer; 
therefore, exploring the metabolism and properties of fatty 
acids can provide new potential pharmacological targets in 
the treatment of different clinical conditions.  
 
FATTY ACIDS IN IMMUNITY 
Growing evidence points to the importance of lipid metab-
olism and signalling in the function of different types of 
immune cells, both in a homeostatic state and during the 
immune response. Fatty acids and their derivatives are of 
particular importance and recent discoveries have high-
lighted their role in the regulation and function of immune 
cells, in particular T lymphocytes (Figure 1). 
 
Sensing and binding 
Fatty acids bind to several surface receptor members of 
the family of G protein coupled receptors (GPCR) [12, 13]. 
Of particular interest is GPR84, which has affinity for fatty 
acyl chain length of 6-14 C (medium chain fatty acids) and 
is expressed by a variety of immune cells, mainly neutro-
phils and monocytes/macrophages, and to a lesser extent, 
by CD4+ and CD8+ T cells. Expression of GPR84 both in hu-
man and mouse monocytes is upregulated upon lipopoly-
saccharide (LPS) stimulation, suggesting that signals trig-
gered by medium chain fatty acids may have a role in 
monocyte/macrophage activation [14]. Moreover, medium 
chain saturated fatty acids such as caproic acid (C6), un-
decanoic acid (C11) and lauric acid (C12), are able to stimu-
late the secretion of interleukin 12 p40 subunit (IL12 p40) 
in mouse LPS-stimulated RAW264.7 cells, showing that 
they can have a role in regulating the activity of different 
immune cells during inflammation [14].  
It has been recently reported that the short chain fatty 
acids acetate (C2), propionate (C3) and butyrate (C4) are 
able to orchestrate the differentiation of CD4+ T cells in 
effector or regulatory cells modulating the activity of his-
tone deacetylases (HDAC) [15]. Short chain fatty acids can 
also inhibit HDAC in T cells leading to the amplification of 
the mTOR pathway, through acetylation of p70 S6 kinase 
and consequent phosphorylation of rS6, all events required 
for the differentiation in T helper 17 (Th17), T helper 1 
(Th1) and IL-10+ T cells [15]. As short chain fatty acids can 
be readily uptaken through the plasma membrane [16], 
their effect was found to be independent of the surface 
receptors GPR41 and GPR43, which can sense acetate, 
butyrate and propionate [17], and have been shown to be 
important in regulating intestinal inflammatory responses 
[18]. These findings identify short chain fatty acids as cru-
cial gut metabolites affecting the balance of effector and 
regulatory T cells and orchestrating the immune response 
in the gut. 
Long chain fatty acids (14-22 C), such as the saturated 
palmitic acid (C16:0) and monounsaturated oleic acid 
(C18:1), can also be sensed by CD36, a fatty acid trans-
locase required for the uptake of fatty acids in the gut [19], 
liver [20], myocardium, skeletal muscle and adipose tissue 
[21, 22]. CD36 expression in endothelial cells (EC) is in-
strumental for the optimal translocation of long chain fatty 
acids from circulation to cardiomyocytes, skeletal muscle 
and adipose tissue, with important consequences for fatty 
acid metabolism, glucose utilization, glucose tolerance and 
insulin sensitivity [23]. CD36 also binds to a range of lipidic 
ligands, such as oxidized phospholipids [24], oxidized LDL 
[25] and native lipoproteins [26]. CD36 was found to be 
particularly important for the activity of phagocytes during 
inflammation, by functioning as a scavenger receptor [27] 
and by cooperating with several Toll-like receptors [28-30]. 
CD36 mutations in humans have been associated with 
CD36 deficiency in platelets and monocytes, with potential 
consequences for their functions [31]. CD36 loss has been 
reported to reduce macrophage infiltration in adipose tis-
sue [32], while pharmacological inhibition of CD36 in vitro 
reduces saturated fatty acid uptake (e.g. palmitic acid 
(16:0) and stearic acid (18:0)) in macrophages and amelio-
rates insulin signalling in adipocytes. More importantly, 
genetic ablation of CD36 in the hematopoietic compart-
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ment led to a reduced infiltration of macrophages and im-
proved insulin signalling in the adipose tissue of mice fed a 
high fat diet (HFD) [32], although it did not reduce the ac-
cumulation of long chain fatty acids [32, 33], suggesting 
that some of the CD36-mediated functions in macrophages 
do not depend on its fatty acid translocase activity. All 
these findings highlight the importance of CD36 as a target 
for the treatment of metabolic disorders with an inflamma-
tory component, such as obesity and diabetes. T cells also 
express CD36 on their surface, with T memory (Tm) cells 
showing lower levels than T effector (Teff) cells [34].  
Fatty acid binding proteins (FABP) are a family of intra-
cellular and extracellular proteins that bind saturated and 
unsaturated fatty acids [35]. It is now clear that these pro-
teins not only buffer and transport fatty acids, but are also 
deeply involved in the regulation of their metabolism with 
consequences for cell signalling, particularly during in-
flammation [36, 37]. Recently, tissue-resident memory Trm 
cells have been shown to be dependent on the activity of 
FABP4 and FABP5 for long-term survival. Pan et al. [38] 
demonstrated that the deficiency of FABP4/5 impairs the 
uptake of fatty acids such as palmitate, by skin CD8+ Trm 
cells, thus reducing their long-term survival in vivo. CD8+ 
Trm cells lacking FABP4/5 fail to increase mitochondrial 
oxidative metabolism in the presence of fatty acids in vitro, 
and their persistence in vivo was significantly reduced due 
to inhibition of β-oxidation. Finally, FABP4 and FABP5 were 
also found upregulated in human CD8+ Trm cells isolated 
from normal and psoriatic skin, confirming the importance 
of fatty acids in the maintenance and longevity of this tis-
sue-resident protective immune population [38]. 
Cellular fatty acids and their metabolites activate dif-
ferent signals via binding peroxisome proliferator-activated 
receptors (PPAR), nuclear receptors involved in the regula-
tion of transcription of genes linked to lipid metabolism 
[39]. PPARα and β/δ are particularly important in cardiac 
muscle, brown adipose tissue and liver, whilst PPARγ is 
more ubiquitously expressed [40-42]. These receptors have 
been proven to be important in the differentiation of a 
number of T cell subsets [43], particularly in informing the 
decision of CD4+ T cells toward differentiating to Th17 or  
T regulatory (Treg) cells [44]. Consistently, Klotz et al. [45] 
FIGURE 1: Fatty acids are crucial to many biological processes occurring in immune cells, particularly T lymphocytes. Short (C2-4)- and me-
dium (C6-14) chain fatty acids (SCFA and MCFA) are able to influence the differentiation of CD4+ in Th1, Th17 and IL-10+ T cells, by downregu-
lating histone deacetylase (HDAC) activity and activating mammalian target of rapamycin (mTOR). The generation of CD8+ tissue resident 
memory T cells (Trm) also relies upon the availability of fatty acids (FA) available for β-oxidation and the presence of the fatty acid binding 
proteins FABP4 and FABP5. The generation of central memory CD8+ T cells (Tm) instead relies upon endogenous fatty acid biosynthesis 
(eFAB), which also provides substrates for β-oxidation, crucial for the long-term survival of these cells. The pathogenicity of Th17 can be also 
regulated by fatty acids: by increasing the activity of fatty acid biosynthesis (FAB) and cholesterol biosynthesis (CBP), and downregulating the 
expression of PPARγ and CD5L, Th17 cells produce IL17 and become more pathogenic, especially in auto-immune diseases such as multiple 
sclerosis and rheumatoid arthritis. Conversely, upregulation of PPARγ and CD5L, and blocking of FAB and CBP, can reduce the pathogenicity 
of Th17 and increase production of IL10. Finally, saturated fatty acids (e.g. palmitate) can enable the migration of T cells towards non-
lymphoid inflamed sites (e.g. joints in arthritis and fat tissue in obesity) where they sustain chronic inflammation; polyunsaturated fatty acids 
(PUFA) can have the opposite effect and inhibit T cell migration, exerting anti-inflammatory properties. 
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have shown that PPARγ regulates the differentiation of 
Th17 T cells, by negatively controlling the activity of RORγt. 
The same report shows that loss of PPARγ increases the 
severity of experimental autoimmune encephalomyelitis 
(EAE) and multiple sclerosis in mouse models, leading to a 
greater infiltration of Th17 cells into the central nervous 
system [45]. Overall, these findings indicate that activation 
of PPARγ with selective agonists can inhibit the differentia-
tion of Th17 cells in autoimmune conditions with a strong 
Th17 component, such as multiple sclerosis, but also 
rheumatoid arthritis and psoriasis, making PPAR receptors 
a very promising pharmacological target in autoimmunity.  
PPARγ was also found to be crucially important for the 
activity of adipose tissue associated- Treg cells, which ex-
press PPARγ at higher level than Treg originating from lym-
phoid organs [46]. Expression of PPARγ was associated 
with a cluster of mRNAs involved mainly in leukocytes mi-
gration and extravasation (Ccr1, Ccr3, Cxcr6, Cxcl2 and 
Cxcl3), lipid metabolism (Pcyt1a, Dgat1) and Il10 transcript. 
Expression of Foxp3 and PPARγ in naïve CD4+ T cells was 
sufficient to induce the same cluster of mRNAs while addi-
tional treatment with PPARγ agonist pioglitazone and 
rosiglitazone further enhanced the enrichment of tran-
scripts involved in fatty acid transport (Cd36, Slc27a2), 
biosynthesis (Lipe, Scd1) and oxidation (Cpt1a). Genetic 
deletion of PPARγ in vivo led to a contraction of the Treg 
population in adipose tissue with a relative increase in the 
number of pro-inflammatory macrophages. Furthermore, 
in obese mice, treatment with pioglitazone enhanced the 
accumulation of Treg in epididymal adipose tissue and their 
expression of CD36. This phenotype was abrogated in 
obese PPAR deficient mice, which also showed a less 
marked reduction of pro-inflammatory macrophages upon 
treatment with pioglitazone, as compared to their wild 
type (wt) counterpart. PPARγ deficient mice did not show 
an improvement in metabolic parameters (insulin re-
sistance, glucose and insulin tolerance) when treated with 
pioglitazone [46]. These findings clearly demonstrate that 
PPARγ is a crucial regulator of the properties of adipose 
tissue associated- Treg cells and its expression in Treg is nec-
essary for the insulin-sensitizing activity of pioglitazone, 
with important consequences for the management of obe-
sity-induced insulin resistance. 
 
Activation and differentiation  
T lymphocytes undergo a clonal expansion upon antigen 
recognition, which is necessary to mount an appropriate 
immune response. This process demands not just energy, 
but also the activation of specific signals required for the 
proper differentiation and activation of the cell. It has been 
shown that activation of the T cell receptor (TCR) is accom-
panied by upregulation of genes involved in the biosynthe-
sis of cholesterol and fatty acids [47]. This anabolic pro-
gramme is orchestrated by sterol regulatory element bind-
ing protein (SREBP) [47]. Interestingly, lack of SREBP by 
genetic inactivation is particularly detrimental to T cells 
undergoing clonal expansion after activation, as it does not 
allow for biosynthesis of cholesterol and fatty acids re-
quired to sustain their energy demands. Moreover, SREBP 
is required for the biosynthesis of cellular membranes, as 
shown by experiments where addition of cholesterol was 
able to rescue the growth of T cells [47]. Also, in vivo, the 
lack of SREBP was responsible for a poor anti-viral re-
sponse against the lymphocytic choriomeningitis virus, 
again demonstrating that the ability of activating an ana-
bolic lipid programme for the biosynthesis of cholesterol 
and fatty acids is a requirement for a proper immune re-
sponse [47]. 
The generation of Tm cells has also been shown to rely 
upon mitochondrial fatty acid β-oxidation [34]. It has been 
shown that Tm cells do not take up extracellular palmitate, 
unlike Teff, highlighting how different T cell subtypes ex-
press different preferences for fatty acid substrates. Sur-
vival of Tm cells was reduced in the presence of the FAS 
inhibitor C75 [48], confirming that these cells rely upon de 
novo fatty acid biosynthesis for survival. Moreover, Tm cells 
utilize glucose to newly synthesise fatty acids to fuel oxida-
tive phosphorylation, thus being independent from extra-
cellular fatty acid uptake. The lipolysis occurring in these 
cells is crucial to their function, and it has been demon-
strated that in Tm cells, lipids associate with lysosomes, 
where lysosomal acid lipase (LAL) produces fatty acids nec-
essary to support β-oxidation. Furthermore, loss of LAL 
activity reduced the survival of Tm cells, without affecting 
Teff cells, and also inhibited the development of Tm cells 
upon infection in vivo [34]. 
Michalek et al. [49] have reported that Teff cells and Treg 
cells exhibit different metabolic requirements for differen-
tiation and function, with the former being more glycolytic 
and the latter relying more on lipid oxidation [49], while 
Berod et al. [50] showed how de novo fatty acid biosynthe-
sis plays a crucial role in determining the differentiation of 
CD4+ T cells to Th17 or Treg Foxp3+ cells. These authors 
showed that inhibition of acetyl-CoA carboxylase (ACC) in 
vitro, using the specific inhibitor Sorafen A, leads to an 
impaired differentiation of Th17, favouring instead the 
differentiation of Foxp3+ Treg cells. CD4+ naïve T cells, cul-
tured in Th17 polarizing conditions in the presence of So-
rafen A, failed to increase the production of IL-17 and up-
regulate genes associated with this lineage, such as 
Hif1alpha and Stat3. To further evaluate the role of ACC as 
a potential therapeutic target, the phenotype of mice lack-
ing ACC1 (cytosolic isoform of the carboxylase required for 
the de novo synthesis of fatty acids [51]) in T cells was ana-
lysed. When compared to wt mice, and after induction of 
EAE, mice lacking ACC1 were found to be protected and did 
not develop any clinical signs of the disease. Similarly, ad-
ministration of the ACC1 inhibitor Sor-S1036 in wt mice 
affected by EAE, resulted in a significant delay in disease 
onset and severity [50]. 
The possibility of exploiting ACC1 as a promising phar-
macological target has also been shown in the context of 
chronic malaria infection [52]. Injection of CD4+ T cells lack-
ing ACC1 in mice infected with Plasmodium chabaudi, re-
sulted in reduced cell survival and was accompanied by 
reduced generation of Tm cells. A similar result was ob-
tained using TOFA, an inhibitor of ACC1, during T cell prim-
ing that increased the number of Teff cells and reduced 
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parasitemia. Inhibition of fatty acid synthesis was shown to 
be particularly detrimental for Tm cells as they rely more on 
newly synthesised fatty acids as compared to Teff cells, sug-
gesting that targeting fatty acid biosynthesis in Tm cells may 
be important in the development of new strategies for 
fighting chronic infections like malaria [52]. These findings 
highlight the importance of fatty acid metabolism for the 
generation of immunological memory and suggest that 
regulation of this pathway is an interesting prospect for the 
development of vaccines.  
The importance of fatty acids in balancing the protec-
tive effects of T cell responses and their pathogenicity was 
addressed by Wang et al., with particular regard to Th17 
cells, which can lead to autoimmunity when they are aber-
rantly activated [53]. In this study, CD5L, a member of the 
scavenger receptor cysteine-rich superfamily [54], was 
identified in a single cell RNA-seq screening as a regulator 
of pathogenicity in Th17 cells and was found expressed 
only in non-pathogenic Th17 cells, both in vitro and in vivo. 
CD5L-/- T cells injected in mice affected by EAE led to a 
more severe phenotype, whilst mice that received wt cells 
did not show any clinical signs of disease. As CD5L can bind 
to FAS [55], the lipidome of wt and CD5L-/- Th17 cells was 
analysed and showed two completely distinct fatty acid 
profiles: the presence of CD5L increased the levels of PUFA 
versus saturated fatty acids and mono-unsaturated fatty 
acids, and reduced cholesterol content. In detail, CD5L is 
able to suppress the cholesterol synthesis pathway. These 
changes affect the activity of RORγt by modulating the 
availability of its ligands and affecting its ability to bind to 
target genes, such as IL-17a and IL-23r, whilst increasing 
binding to IL-10, making of CD5L a repressor of pathogenic-
ity of Th17 cells [53]. Overall, these findings show how 
potent the effect of fatty acid metabolism is on the biology 
of immune cells, not only as source of energy, but also by 
sustaining the molecular signals required for differentiation 
and function.   
Direct exposure to palmitate was found to be responsi-
ble for the biased differentiation of CD4+ T cells towards 
the expansion of a detrimental, pro-inflammatory effector 
memory population in obesity [56]. These aberrant T lym-
phocytes eagerly migrate to non-lymphoid, inflammatory 
sites (such as the fat tissue during obesity), where they 
sustain a low-grade chronic inflammation which is a hall-
mark of many metabolic disorders, such as obesity, type II 
diabetes and atherosclerosis [56]. 
In obesity, there are many different immune cells that 
play a role in sustaining the inflammatory response within 
the adipose tissue. The stress response triggered by hyper-
trophy in both adipocytes and stromal cells [57, 58] is re-
sponsible for the recruitment and activation of CD8+ T cells, 
Th1 cells, and natural killer (NK) cells, leading to the accu-
mulation of pro-inflammatory M1 macrophages [59-61]. In 
2016, another population of immune cells was demon-
strated to play an important role in the maintenance of 
obesity, the group 1 innate lymphoid cells (ILC1) [62]. The 
authors showed that residing ILC1 proliferate and accumu-
late locally, in the adipose depots, during HFD-induced 
obesity and are the main producer of IFN-γ. The sustained 
production of IFN-γ is responsible for the polarization of 
macrophages towards a pro-inflammatory M1 phenotype 
which then contributes to the development of obesity-
associated insulin resistance. The axis IL12-STAT4 was 
found to be the molecular switch for the production of  
IFN-γ and the consequent M1 polarization of macrophages 
[62]. This is another example of how fat accumulation can 
deeply change the biological behaviour of immune cells, 
interfering with their homeostatic function, with great con-
sequences for the establishment of pathological conditions. 
B lymphocytes have also been shown to have an im-
portant role in the development of age-induced fat accu-
mulation and insulin resistance [63]. Carter and co-workers 
[63] found that aging mice (between 6 and 12 months old) 
have higher number of follicular B2 cells in circulation and 
epididymal white adipose tissue. The expansion of this  
B cell population correlated with a higher plasma level of 
IgG (in particular IgG2c) and glucose intolerance. Moreover, 
these cells displayed a greater expression of OcaB (B-cell-
specific nuclear cofactor Oct coactivator – crucial for B cell 
maturation [64] and IgG production [65]). Genetic ablation 
of OcaB resulted in the abrogation of this phenotype, with 
improvement of glucose intolerance and insulin sensitivity, 
and reduced fat accumulation during aging due to in-
creased energy expenditure. OcaB-/- mice showed a higher 
core body temperature and increased metabolic activity in 
their adipose tissue depots, as shown by enhanced uptake 
of bromopalmitate and glucose. Replenishment of OcaB-/- 
mice with OcaB+/+ B cells, via bone marrow transfer, was 
sufficient to re-induce body weight gain, glucose intoler-
ance and insulin insensitivity [63]. 
Recently, omega-3 (n-3) PUFA have been shown to al-
ter the trafficking of activated CD4+ T cells to fat tissue [66]. 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) were both able to reduce the number of effector 
memory CD4+ T cells and change the array of bioactive 
lipids produced in lymphoid organs and adipose tissues of 
animals following nutritional supplementation. EPA and 
DHA were also able to prevent the polarisation of T cells 
and activation of the small Rho GTPases Rhoα and Rac1, 
both events required for migration to target/inflamed tis-
sue [66]. EPA and DHA have also been shown to increase 
the infiltration of CD4+ and CD8+ T cells in UV irradiated 
human skin, potentially through changes in the network of 
cutaneous bioactive lipids [67].  
N-3 PUFA have also been shown to boost B cell anti-
body production [68] and B cell response [69], but the dif-
ferential contribution of EPA and DHA to this phenotype 
was only recently addressed by Teague et al. [70]. The au-
thors showed that a diet enriched with either EPA or DHA 
resulted in accumulation of EPA and DHA ethyl esters in  
B cells at the expense of n-6 PUFA. EPA and DHA were also 
able to increase the frequency of specific subsets of B cells 
(in particular IgM+ IgD- CD21low CD23- B cells) and while 
both of them increased the production of IgM, only EPA 
boosted the production of IgA. Moreover, after ten weeks 
supplementation, EPA and DHA increased B cell TNFα and 
IL6 production, but only DHA induced the production of 
IL10 [70]. The differential activity of n-3 PUFAs on B cells 
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bears important consequences for application in clinical 
settings, being now clear that EPA and DHA are not biologi-
cally equivalent. 
The availability of fatty acids can impact the function of 
many proteins through post translational modifications 
including S-acylation [71]. The most common protein acyla-
tion is palmitoylation although use of different acyl groups 
has been reported [72, 73]. Palmitoylation is catalysed by 
aspartate–histidine–histidine–cysteine (DHHC) acyl trans-
ferases and can deeply affect the trafficking, localisation 
and activity of proteins [74]. Recently, Chopard et al. have 
highlighted how palmitoylation is important for HIV-1 in-
fection [75]. The viral protein Tat can be secreted by in-
fected cells and subsequently be endocytosed by many 
different cell types altering the expression of genes related 
to HIV-associated cancers [76]. Tat can also inhibit the cel-
lular processes that rely upon phosphatidylinositol (4,5) 
bisphosphate (PI(4,5)P2) for phagocytosis and neurosecre-
tion [77]. Accumulation of Tat in uninfected cells (e.g.  
T cells, macrophages and neurosecretory cells) is attributed 
to its palmitoylation by S-acyl transferase DHHC-20 on 
Cys31, which stabilises the interaction with PI(4,5)P2 thus 
preventing Tat secretion. The persistence of Tat on plasma 
membranes and its stable interaction with PI(4,5)P2 inter-
feres with PI(4,5)P2-dependent membrane trafficking, with 
important consequences for Tat-mediated toxicity in HIV-1 
infected individuals [75]. 
 
FATTY ACIDS IN CANCER 
It is widely accepted that cancer cells undergo a profound 
metabolic reprogramming, which is now considered a 
hallmark of the disease [78]. The so-called Warburg effect 
is one of the most remarkable metabolic phenotypes of 
cancer cells, consisting of prompt uptake of glucose and 
upregulation of glycolysis even in the presence of oxygen, 
with consequent production of lactate and its release into 
the tumour microenvironment [79, 80]. 
Growing evidence demonstrates the importance of li-
pid metabolism and lipid signalling in cancer cell biology, 
highlighting the great potential of lipid metabolising en-
zymes, transporters and receptors as therapeutic targets. 
Cancer cells show changes in fatty acid and cholesterol 
metabolism, and this impacts upon their ability to grow 
and proliferate [81-83] (Figure 2). 
 
Sensing and binding 
Fatty acid sensing is crucial for cancer cells, and different 
studies have shown the importance of lipoprotein recep-
tors and FABP for cancer cell survival [84-87]. Saturated 
and unsaturated long chain fatty acids differentially regu-
late the transcriptional activity of the retinoic acid receptor 
RAR and PPARβ/δ, through FABP5. Although saturated 
fatty acids block FABP5 and inhibit PPARβ/δ, unsaturated 
fatty acids activate PPARβ/δ. The result is that saturated 
fatty acids, by activating RAR and inhibiting PPARβ/δ, are 
able to suppress the growth of cancer cells [88]. Recently, a 
role for FABP5 in promoting cancer growth through the 
estrogen-related receptor α (ERRα)-dependent upregula-
tion of metabolic genes has been reported in prostate can-
cer [89]. 
CD36 represents another promising pharmacological 
target for interfering with the fatty acid uptake by cancer 
cells, and very recently, Watt and co-workers showed how 
targeting CD36 could be an effective strategy against pros-
tate cancer [90]. In this study, the authors used patients’ 
samples and xenograft models to demonstrate that in-
crease in uptake and utilization of fatty acids in prostate 
cancer is due, at least in part, to expression of CD36, and 
that the presence of this transporter correlates with ag-
gressive disease. Deleting CD36 or using a blocking mono-
clonal antibody slowed cancer progression and disease 
severity [90]. 
 
Biosynthesis and metabolism 
Fatty acid biosynthesis plays a pivotal role in cancer biology 
and it is not surprising that inhibition of this process repre-
sents an appealing pharmacological avenue [91]. SREBPs 
have been shown to be important for cancer survival and 
progression [92, 93]. More recently, Li et al. [94] have 
pointed to their importance in hepatocellular carcinoma 
(HCC). By blocking SREBP, either genetically or pharmaco-
logically, the progression of HCC was remarkably inhibited 
together with downregulation of tumour-promoting in-
flammatory cytokines, such as IL-6, TNFα and IL-1β [94].  
Inhibition of FAS, leading to impaired de novo biosyn-
thesis has been explored as a therapeutic strategy for met-
astatic castration-resistant prostate cancer (mCRPC) [95], 
as demonstrated by the development of inhibitors that 
reduced the growth of human CRPC xenograft and human 
mCRPC-derived organoids [95]. The importance of fatty 
acid biosynthesis was further addressed in a recent study 
showing how cancer cells can utilize different fatty acyl-
CoA desaturases (FADS) in order to sustain proliferation 
[96]. Several cell lines, including mouse HCC and primary 
human liver and lung cancer cell lines, were found to be 
independent from the activity of stearoyl-CoA desaturase 
(SCD), instead they were able to desaturate palmitate to 
the unusual sapienic acid (rather than to palmitoleic acid) 
through the activity of FADS2 [97]. Inhibition of both de-
saturases, SCD and FADS2, resulted in reduced cancer 
growth in vivo, suggesting that targeting of multiple path-
ways may be needed in order to effectively impair cancer 
metabolic plasticity [96]. 
Utilising fatty acids for energy production, in particular 
via β-oxidation, is important for cancer cell growth and has 
been considered a target for the development of new 
therapies in various cancers including B cell lymphoma [98], 
leukemia [99], prostate cancer [100], ovarian cancer [101] 
and pancreatic cancer [102]. Of particular interest in this 
context is the understanding of the transcriptional regula-
tion of β-oxidation in cancer, as this has been associated 
with the over-expression of certain oncogenic transcription 
factors, such as MYC and β-catenin. 
The oncogene MYC is responsible for alteration of me-
tabolism during tumorigenesis [103, 104]. Recently, 
Camarda et al. [105] showed that MYC-overexpressing 
triple-negative breast cancer (TNBC) is highly dependent 
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on β-oxidation for survival. To assess the role of MYC in 
TNBC, the authors analysed the metabolites produced by 
breast tumours and normal mammary gland from a condi-
tional transgenic model of MYC-overexpressing tumours 
and reported that MYC-TNBC tumours are enriched in acyl-
carnitines, metabolites of the β-oxidation pathway [105]. 
In human samples, TNBC tumours also appear to upregu-
late genes responsible for the activation of β-oxidation and 
downregulate genes of fatty acid biosynthesis, both at 
mRNA and protein level. Finally, inhibiting β-oxidation, 
either using the inhibitor etomoxir or knocking-down car-
nitine palmitoyl transferase 1B, proved to be detrimental 
for the energy production and survival of cancer cells in 
vitro and also in vivo [105]. 
Of particular interest is also the finding of β-catenin 
(CTNNB1)-mutated HCC dependence on fatty acids [106]. It 
was reported that these tumours do not comply with the 
Warburg effect, they are not glycolytic, and activate a 
strong fatty acid catabolic programme by increasing the 
flux of β-oxidation. This phenotype was observed in mice 
recapitulating β-catenin mutated HCC (by inactivation of 
Apc - [107]) and further confirmed in human samples, 
where the same metabolic signature was found. Loss of 
PPARα, a downstream target of β-catenin, was sufficient to 
blunt the upregulation of β-oxidation and reduce the for-
mation and progression of tumours. Pharmacological inhi-
bition of β-oxidation with etomoxir exerted the same ef-
fect on tumour growth [106].  
 
Cancer immunology  
The importance of fatty acid metabolism in regulating the 
functions of immune cells was recently shown to influence 
the ability of the immune system to clear tumours. The 
interaction between immune and cancer cells takes place 
in the tumour microenvironment, which is able to influ-
ence the proliferation and activation of immune cells. 
Pacella et al. have shown how the tumour microenviron-
ment favours the expansion of a Treg cell population over a 
conventional T cell (Tconv) population, which would be able 
to fight the tumour [108]. Treg are able to survive better 
than Tconv in the tumour microenvironment because of 
their ability to utilize glucose for fatty acid biosynthesis. Treg 
indeed rely on fatty acid biosynthesis more than their con-
ventional counterparts and the authors confirmed that 
FIGURE 2: Cancer cells rely upon fatty acids (FA) for proliferation, survival and metastasis, and utilise them for the production of energy 
and membrane maintenance; consequently, both fatty acid biosynthesis (FAB) and β-oxidation are found increased in many cancers. The 
expression of CD36 and fatty acid binding proteins (FABP) has been associated with cancer growth. The activity of fatty acyl-CoA desaturases 
(FADS) sustains FAB, promoting cancer growth and survival. As shown on the left side of the figure, some cancers put in place a transcrip-
tional programme, governed by master regulators such as MYC and β-catenin, in order to boost the activity of FAB and β-oxidation and, 
generally, utilisation of fatty acids, supporting cancer growth. Finally, on the right side of the figure how cancer cells utilise fatty acids to 
support their migration and growth in secondary sites is shown; in this context, the expression of CD36 is central for the dissemination of 
cancer cells from the primary tumour and the establishment and growth of metastasis. The activity of enzymes involved in phospholipid 
hydrolysis (Phospholipase D – PLD; cytosolic phospholipase A2α – cPLA2α; phospholipase Cγ1 – PLCγ1), in fatty acid biosynthesis (ATP citrate 
lyase – ACLY; acetyl-CoA carboxylase – ACC; fatty acid synthase – FAS) and in their catabolism (Carnitine palmitoyl transferase 1 – CPT-1), has 
been proven fundamental for dissemination and metastasis establishment. 
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activated Treg isolated from human liver cancers express a 
unique gene signature supporting glycolysis and lipid bio-
synthesis [108]. 
The relationship between lipid metabolism, cancer and 
the immune system has become the focus of growing re-
search activity in recent years, following epidemiological 
studies revealing the association of cancer and obesity, and 
showing that obesity is a potent risk factor for developing 
cancer [109, 110]. Recently, a new mechanism explaining 
how fatty acid accumulation blunts the immune response 
in obesity has been described, suggesting that obesity can 
significantly impair the cytotoxic activity of NK cells [111]. 
Feeding mice a HFD altered in NK cells the expression of 
genes involved in lipid metabolism and trafficking, and 
upregulated PPARα/δ target genes involved in lipid-droplet 
formation (Lipe and Plin2) and lipid uptake (Cd36, Lpl and 
Lrp4). Human NK cells from obese patients were found to 
accumulate more lipid droplets and were less able to kill 
cancer cells, an effect mediated via lipid driven mTORC1 
inhibition. Blocking the translocation of fatty acids to mito-
chondria using etomoxir was sufficient to restore the cyto-
toxic activity of NK cells [111].  
However, obesity is also well known to induce a state 
of low-grade chronic inflammation, with prolonged and 
exacerbated innate and adaptive immune responses [56, 
112], which may promote obesity-driven diseases, includ-
ing cancer. How these aspects of obesity control of innate 
and adaptive response are reconciled, and whether the 
effect on NK is specific to this cell type, are points of inter-
est and remain unanswered. 
Palmitoylation was found to be important in the con-
text of cancer immunotherapy. Yao and colleagues demon-
strated that programmed death ligand 1 (PD-L1), one of 
the main targets in cancer immunotherapy [113], can be 
palmitoylated in colorectal cancer cells by DHHC3 and that 
this modification increases its stability by preventing lyso-
somal degradation [114]. Inhibition of PD-L1 palmitoylation, 
either pharmacologically or by genetic ablation of DHHC3, 
was able to increase the T cell cytotoxicity against cancer 
cells in vitro, and to reduce tumour growth also in vivo. The 
authors developed a synthetic peptide able to specifically 
target DHHC3 and block PD-L1 palmitoylation, demonstrat-
ing that targeting this post-translational modification can 
be a feasible way of suppressing PD-L1-dependent immune 
evasion of tumour cells [114]. 
 
Metastatic disease 
Of particular relevance, especially from a clinical and ther-
apeutic standpoint, is the association between dysregulat-
ed fatty acid metabolism and cancer metastasis. Several 
studies have highlighted the importance of fatty acids in 
the growth of secondary tumours, showing how enzymes 
involved in fatty acid biosynthesis and catabolism are cru-
cial in this process (Figure 2). In the context of fatty acid 
synthesis, the enzyme ATP citrate lyase (ACLY – responsible 
for the conversion of citrate to oxaloacetate and cytosolic 
acetyl-CoA) has been associated with metastatic disease in 
gastric adenocarcinoma (GA) [115]. It has been proposed 
that ACLY could be used as biomarker for the prediction of 
progression and prognosis of GA, as it was found overex-
pressed in patients’ cancer tissue as compared to normal 
tissues, and its expression correlated negatively with pa-
tient survival [115]. In another study, ACLY was shown to 
be a potential therapeutic target. Indeed, its inhibition by 
microRNA-22 was able to suppress growth and invasion in 
different types of cancer cells [116]. In clinical samples, the 
authors observed that upregulation of ACLY correlates with 
the downregulation of miR-22. Moreover, in animal models 
of osteosarcoma and prostate cancer, treatment with miR-
22 reduced tumour growth and formation of distant me-
tastasis, and prolonged survival [116]. ACLY was also found 
to be a novel interactor of the low molecular weight iso-
form of cyclin E (LMW-E). This interaction allows breast 
cancer cells to store lipids necessary for growth, migration 
and invasion both in vitro and in vivo, while in clinical sam-
ples a strong correlation between worse prognosis, expres-
sion of LMW-E and accumulation of lipids droplets (a con-
sequence of the increased activity of ACLY) was observed 
[117]. 
Another enzyme that could prove to be a good diag-
nostic marker as well as a potential therapeutic target is 
the ACC (responsible for the carboxylation of acetyl-CoA to 
malonyl-CoA). Expression of phospho-ACC was found to 
correlate with a worse overall survival in squamous cell 
carcinoma of the head and neck, in patients with node 
metastasis [118]. Recently, ACC was associated with ag-
gressiveness in HCC and also with poor survival and disease 
recurrence, making it a potential prognostic marker and 
therapeutic target as well [119].  
FAS is upregulated and associated with malignant pro-
gression in cancer: inhibition of FAS reduced invasion and 
migration of HCC [120], and was found responsible of pro-
moting peritoneal metastasis in ovarian cancer through 
induction of epithelial to mesenchymal transition (EMT) 
[121]. Similarly, breast cancer cells undergo EMT in a FAS -
dependent manner [122]. FAS was also associated with 
Wnt signalling and metastatic progression in colorectal 
cancer [123]. In the context of prostate cancer, Ahmad and 
co-workers found that PPARγ-mediated expression of FAS 
sustains the growth of prostate cancer cells and confers 
poor prognosis for metastatic prostate cancer [124]. Fur-
thermore, Sounni et al. have shown how inhibition of FAS 
can confer advantage in overcoming tumour adaptation to 
anti-angiogenic treatment [125]. In this study, the authors 
found that interrupting the administration of anti-
angiogenic drugs, such as sunitinib and sorafenib, led to a 
shift in the tumour metabolism responsible for an increase 
in fatty acid biosynthesis associated with tumour re-growth 
and dissemination, which often occurs in cancer patients 
after anti-angiogenic treatment withdrawal [125]. Pharma-
cological or genetic inhibition of FAS was able to suppress 
tumour growth and dissemination in different cancer mod-
els, highlighting a potential new strategy for treating can-
cer after withdrawal of anti-angiogenic drugs.  
Phospholipid hydrolysis is important for metastatic 
progression, thus providing different potential targets for 
therapeutic intervention. Phospholipase D (PLD), through 
the release of phosphatidic acid and cooperation with Grb2 
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and Rac2 (events that affect the plasma-membrane plastic-
ity and actin polymerization), was found to play a role in 
metastasis in several cancers. Henkels et al. [126] have 
demonstrated that PLD drives tumour growth and metas-
tasis formation in a human breast cancer xenograft model. 
Deletion of PLD2 from metastatic cells suppressed the for-
mation of metastasis and, consistently, its overexpression 
in non-metastatic cells led to the acquisition of a malignant 
metastatic phenotype. Furthermore, pharmacological inhi-
bition of PLD2 was sufficient to suppress tumour growth 
and dissemination [126] while PLD2 has also been shown 
to regulate the expression of HIF1α in renal cancer cells 
[127]. Other phospholipases have been found to be im-
portant in metastasis formation; pharmacological inhibi-
tion of cytosolic phospholipase A2α (cPLA2α) with the in-
hibitor CIX, was able to reduce the migratory capabilities of 
a murine metastatic breast cancer cell line by interfering 
with Toll-like receptor- and type I interferon-mediated 
signals [128]. cPLA2α was found overexpressed also in hu-
man breast cancer samples and in invasive breast cancer 
cell lines [129]. Its inhibition significantly reduced the mi-
gration of metastatic cell lines in vitro, whilst its stable 
knockdown inhibited the EMT necessary for the acquisition 
of the migratory phenotype. Indeed, cPLA2α was found to 
be necessary for the TGFβ-induced EMT by activating the 
PI3K/Akt/GSK3β pathway, both in vitro and in vivo [129]. 
Phospholipase Cγ1 (PLCγ1) was also associated to meta-
static risk in breast cancer patients [130]. Higher expres-
sion of PLCγ1 and its activated forms in tumour samples, 
was associated with a higher frequency of distant metasta-
sis, highlighting how PLCγ1 not only could be a potential 
therapeutic target, but also a prognostic marker for meta-
static risk in breast cancer patients [130].  
Inhibition of β-oxidation also represents a potential 
therapeutic for interventions preventing cancer metastasis. 
Carnitine palmitoyl transferases (CPT) are responsible for 
the transport of fatty acids to the mitochondria for β-
oxidation. In TNBC cells, mitochondrial β-oxidation is up-
regulated in order to produce sufficient amounts of ATP 
necessary for survival and proliferation, leading to activa-
tion of Src. Inhibition of CPT-1 and -2, by specific inhibitors 
or genetic knock-down, was able to prevent Src activation, 
tumour growth and also metastasis formation [131].  
The importance of lipids in metastatic spreading was 
further demonstrated in a recent report exploring lesions 
generated in the oral cavity of mice after implantation of 
cells isolated from human oral carcinomas [132]. They 
found that a subset of CD44+ cells was characterized by the 
expression of genes involved in proliferation, lymphatic 
metastasis and neoplasm metastasis. Furthermore, these 
cells also upregulated genes involved in the metabolism 
and translocation of fatty acids, as well as receptors in-
volved in fatty acid uptake, such as CD36. CD36 was found 
to be crucial for metastasis formation, enabling cells with 
low metastatic potential to significantly increase their ca-
pacity to colonize lymph nodes upon overexpression. Con-
sistently, knock down of CD36 greatly reduced metastasis 
formation. Importantly, this effect was only observed in 
secondary tumours, with little or no effect on the growth 
of primary lesions, pointing to the specific role of CD36 in 
metastasis. When mice were fed a HFD (enriched in fatty 
acids) or cells were treated with saturated fatty acids such 
as palmitic acid, the number of CD36+ cells and metastasis 
was significantly increased. While both CD36+ and CD36- 
cells were able to form primary tumours, only the CD36+ 
population produced metastasis; administration of two 
different neutralizing antibodies against CD36 completely 
inhibited metastasis formation or their size and number 
when metastasis where already established. Finally, as 
upregulation of CD36 correlates with poor prognosis and 
survival rate in patients with different cancers, and that its 
amplification correlates with metastasis in many human 
cancers, CD36 appears to be an interesting target for the 
management of metastatic disease [132]. Several other 
reports have demonstrated a strong correlation between 
aberrant lipid metabolism, EMT and metastasis formation 
[133-136], also highlighting the importance of the research 
in this field to exploit lipid metabolism as a therapeutic 
target. 
 
CONCLUSIONS AND FUTURE PERSPECTIVES 
In the context of immunology, two main conclusions can 
be drawn regarding the importance of fatty acids for im-
mune cells: the generation of immunological memory and 
the differentiation in specific T cell subsets (Figure 1).  
With regard to the generation of Tm cells, the majority 
of reports to date suggest the dependence of these cells on 
fatty acid β-oxidation and fatty acid biosynthesis mostly as 
energy source for survival. This finding is of great im-
portance for research questions trying to better under-
stand and manipulate the generation of memory in differ-
ent pathological contexts. As inhibition of fatty acid biosyn-
thesis is highly detrimental to Tm cells, improving or pro-
tecting the activity of this pathway through the develop-
ment of agonists or via administering substrates to boost it 
and help building an efficient memory compartment, can 
provide opportunities for the development of therapeutics 
to combat chronic disease. 
Equally important is the variety of fatty acid substrates 
and their role in dictating the differentiation of T cells, 
which can be exploited for the generation of clinical inter-
ventions aimed at controlling the pathogenicity of aberrant 
T cells in inflammatory conditions. This may be of particu-
lar relevance to auto-immune diseases, where the balance 
between Th17 and Treg cells is crucial. Activation of PPARγ 
and inhibition of ACC1 could become a good strategy to 
block the generation of Th17 cells [45, 50]. This approach 
can also improve the generation of protective Treg cells [50]. 
The receptor CD5L has also been found to be a repressor of 
the pathogenicity of Th17 cells by regulating fatty acid and 
cholesterol metabolism [53].  
Other immune cell types, such as ILC1 and B cells, are 
also important in the establishment of metabolic disorders, 
particularly obesity and insulin resistance [62, 63]. Under-
standing the mechanisms by which these cell types utilize 
fatty acids and appreciating their exact involvement in 
maintaining adipose tissue inflammation, typical of obesity, 
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will provide useful insights for studies aiming to combat 
this condition. Further research in the field of immunology 
and fatty acid metabolism will provide valuable new infor-
mation and, more importantly, identify new targets to ma-
nipulate the fatty acid metabolic pathways in order to fine 
balance the generation and function of diverse immuno-
logical populations. 
Cancer cells also rely upon fatty acids for the produc-
tion of ATP, which they require in great amounts to meet 
the energy demand necessary for a high proliferation rate, 
in the relatively nutrient-poor tumour microenvironment. 
Inhibiting uptake, biosynthesis and/or utilisation of fatty 
acids, via targeting the relevant enzymes, receptors and 
FABP, represents possible strategies to fight cancer (Figure 
2). 
The inhibition of receptors like CD36 and enzymes in-
volved in fatty acid biosynthesis has shown encouraging 
results in certain cancers (e.g. prostate cancer- [90]) where 
fatty acids appear to be important sources of energy to 
sustain proliferation and survival [91]. The consumption of 
fatty acids via β-oxidation is also a very important metabol-
ic pathway in cancer cells and that is why some cancers 
display an entire transcriptional programme aimed at utiliz-
ing fatty acids for proliferation [105, 106]. This is the case 
of the two transcription factors MYC and β-catenin in 
breast cancer [105] and HCC [106], respectively, both 
strongly promoting β-oxidation.  
Despite their dependence on certain metabolites, such 
as glucose and diverse types of fatty acids, cancer cells can 
easily adapt to the fluctuation of nutrients in the tumour 
microenvironment. The work from Vriens et al. [96] shows 
that cancer cells can use alternative pathways and sub-
strates and that only inhibiting both canonical and alterna-
tive signals can be a successful strategy to overcome the 
metabolic plasticity of cancer cells. Thus, it is evident that 
along trying to discover new ways of inhibiting canonical 
pathways, we also need to explore new non-canonical 
pathways that tumours may exploit for growth and metas-
tasis. 
S-acylation is a modification important for the regula-
tion of protein trafficking and function, providing new 
pharmacological targets that can be exploited in the con-
text of a wide range of pathological conditions, spanning 
from infection to cancer [75, 114]. Inhibition of this process 
by limiting the availability of fatty acids or direct pharma-
cological inhibition of acyltransferases, could prove a viable 
approach applicable to different clinical scenarios.  
Metastatic disease represents one of the greatest chal-
lenges of our time, and it is exciting to see an increased 
number of reports showing that fatty acid uptake and me-
tabolism are actively involved in this process. Inhibition of 
several enzymes, both of the fatty acid biosynthesis and  
β-oxidation pathways, can reduce metastasis in many dif-
ferent cancers, while targeting the receptor CD36 repre-
sents an efficient strategy for blocking their generation and 
growth [132].  
Future research needs to focus on the most promising 
targets in order to develop efficient pharmacological tools 
that can be used in a number of pathological contexts. We 
also need to further dissect the molecular mechanisms 
regulating the biosynthesis and catabolism of fatty acids, in 
order to discover new targets and improve the strategies 
that would allow us to modulate these processes when 
they become aberrant. 
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